An anticancer drug screening program based on the use of multiple panels of human solid tumor cell lines was developed in the United States, 1) and a similar system using a panel of 60 human tumor cell lines organized into subpanels representing leukemia, melanoma, and cancers of the lung, colon, kidney, ovary, and central nervous system was also developed. 2) Vassilev et al.
: down-regulation of p16/Rb, mutation of the p53 gene, modulation of apoptosis and sensitivity to chemical agents. Some post-immortal LCLs develop the ability to form colonies in agarose, and even become tumorigenic by developing the ability to grow in nude mice. Notably, pre-immortal LCL cells share various characteristics with normal B-lymphoblasts generated in vivo by antigen stimulation, providing a basis to use pre-immortal LCLs as a control cell line representing actively proliferating normal lymphoblasts. 6, 18) Normal lymphoblasts and LCL cells share the following characteristics: lymphoblastoid morphology, surface immunoglobulin, secretion of immunoglobulin, a limited lifespan (mortal), negative or low telomerase activity and normal diploid chromosomes. If pre-and post-immortal LCLs derived from a common cell line show different cytotoxicity against anticancer agents, the difference is considered to be solely due to immortalization. Therefore, we used post-immortal LCLs (post-LCLs) as a model of lymphoma and pre-immortal LCLs (pre-LCLs) as a control.
Anticancer agents are roughly divided into two groups: 1) DNA-modifying agents that modify DNA by nicking DNA to create a strand break (e.g., by camptothecin, etoposide, bleomycin), by alkylating DNA (e.g., by melphalan), by being incorporated into DNA sequence instead of normal DNA precursors (e.g., by fluorouracil, 19) thioguanine 20) ) or by inserting into double strand DNA by intercalation (e.g., by actinomycin D); and 2) DNA-non-modifying agents 21) that have anticancer activity by affecting the cytoplasmic constituents, including microtubules (e.g., by colchicine, vincristine, paclitaxel) and by inhibiting the synthesis of DNA precursors (e.g., by methotrexate). Fluorouracil and thiguanine have also the activity to inhibit the synthesis of DNA precursors. 21) In this study we aimed to show that these DNA-modifying and DNA-non-modifying agents have different modes of action with pre-and post-LCLs. We also suggest that pre-and post-LCLs are used as tools to screen and assess anticancer agents.
MATERIALS AND METHODS

Anticancer Agents
The following anticancer agents were obtained from Sigma Chemical Co., Ltd. (St. Louis, Missouri, U.S.A.): melphalan, thioguanine, fluorouracil, methotrexate, actinomycin D, bleomycin, colchicine, vincristine, etoposide, camptothecin, paclitaxel. These agents were dissolved in dimethyloxide (DMSO) before use.
Cell Lines The LCLs were reported previously, 12, 13, 18) including their characteristics, such as telomerase activity and telomere length. Table 1 compares the characteristics of post-N0005, post-N6803 and post-N6803-2 with their counterparts, pre-N0005 and pre-N6803. 13, 14, 16) All post-LCLs had high telomerase activity, abnormal chromosomes, and down regulation of p16/pRb. Both post-N0005 and post-N6803 form colonies in soft agarose medium and post-N6803 grow in nude mice. 16) Post-N0005 has a mutation of the p53 gene. Notably, post-N6803-2, derived from pre-N6803, has neither colony-forming activity in soft agarose medium nor growth activity in nude mice, which are the characteristics of post-N6803. 16) The method to establish LCLs was reported previously. 12) Briefly, peripheral blood cells were infected with EBV propagated in marmoset cell line B95-8 4) in the presence of 200 ng/ml of ciclosporin (Sandoz, Switzerland). Established LCL cells were cultured in 5 ml RPMI1640 medium (Nissui Pharmaceutical Co., Ltd., Tokyo) supplemented with fetal calf serum (Gibco) in 25 cm 2 bottles (Corning, NY, U.S.A.) that stood on a level surface. The cells were passaged twice a week by exchanging half a cell suspension with fresh medium. A T-cell leukemia cell line, Molt-4, was used as a reference. Fibroblasts TIG-3, derived from human fetal lung, and HeLa cells were cultured with Dulbecco's modified Eagle's medium (Sigma) containing 10% fetal bovine serum (Gibco) containing gentamycin. All cell lines, except preand post-N0005, were used as references of N0005.
Cytotoxicity Assay Cultured cells were harvested two days after a medium change, and 100 ml of cell suspension were seeded to each well of a 96-well culture plate on day 0. The number of cells in each well was: 50000 pre-N0005; 25000 post-N0005; 5000 TIG; 1500 HeLa. On day 1, an anticancer agent in 10 ml DMSO was added to each well and 10 ml DMSO without the agent was added to control wells. On day 3, the number of viable cells was assessed by using WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disufophenyl)-2H-tetrazolium, monosodium salt) by using the kit protocol (Nacalai Tesque Co., Ltd., Kyoto). Briefly, 10 ml of WST-8 solution was added to each well, and then the plates were incubated at 37°C for 3-4 h in a 7.5% CO 2 incubator atmosphere. The absorbance was measured by using a Multilabel counter ARVO HTS (Perkin Elmer) at a test wavelength of 450 nm with a reference wavelength of 620 nm. To determine the IC 50 , the final concentration of the anticancer test agent was serially diluted usually by 1/2 by medium and a similar dilution of DMSO without the agent was used for the controls without the agent. Each assay, as well as the whole experiment, was done at least three times, giving more than nine values of IC 50 .
Analysis by Flow Cytometry The cells were fixed with 70% ethanol at 4°C for 1 h. A 25 ml aliquot of 10 mg/ml RNase (Sigma) solution was added to a 1 ml cell suspension (1ϫ10 6 /ml) in phosphatebuffered saline, and the mixture was incubated at 37°C for 30 min. Propidium iodide (Sigma) solution (0.1 ml at 500 mg/ml) was added to the cell suspension, and then the mixture stood at 4°C for 30 min in the dark. The cell cycle distribution was analyzed by using a Coulter Epics XL flow cytometer (Beckman Coulter Co., Ltd, Tokyo).
Statistical Analysis A Student t test was done for the values of IC 50 of two different groups, including between pre-and post-N0005, between pre-N0005 and Molt-4, between pre-and post-N6803 and between TIG-3 and HeLa. Figures 1A and B show profiles of the flow cytometry analysis of pre-and post-N0005 treated with or without various anticancer agents. Pre-N0005 cells are diploid (2n), but post-N0005 cells are near tetraploid (4n). Both colchicine and paclitaxel induced accumulation of G2/M cells. In cells treated with camptothecin and actinomycin D, G1/S was stopped with the apparent disappearance of a G2/M peak. The mode of action of anticancer agents was similar in pre-and post-N0005 cell lines as judged by the profiles of flow cytometry. Figures 2A and B show the effect of 11 anticancer agents on pre-and post-N0005. Three G2/M inhibitors (colchicine, vincristine and paclitaxel) and one G1/S inhibitor (methotrexate) showed similar levels of cytotoxicity in pre-and post-N0005 ( Fig. 2A) . Tables 2 and 3 summarize the values of Fig. 2 ; the tables show, for convenience, the IC 50 ratio (pre-/post-). An IC 50 ratio less than 1 means that an agent shows stronger cytotoxicity in pre-than post-N0005 cells, and an IC 50 ratio of about 1 means that an agent has a toxicity similar in pre-and post-N0005. However, seven G1/S inhibitors (fluorouracil, thioguanine, melphalan, bleomycin, actinomycin D, camptothecin and etoposide) showed markedly stronger cytotoxicity in pre-than post-N0005 (Fig. 2B) . The difference in pre-and post-N0005 was statistically significant (pϽ0.001) ( Table 2) . Especially marked was the difference in the effect of bleomycin in preand post-N0005 cells. Methotrexate and the three G2/M inhibitors do not, but the remaining seven G1/S inhibitors do, directly modify DNA strands. Thus, for these 11 anticancer agents, all DNA-modifying agents showed stronger cytotoxicity in pre-than post-N0005 (IC 50 ratio of less than one), but all DNA-non-modifying agents showed similar cytotoxicity in both pre-N0005 and post-N0005 (IC 50 ratio of nearly 1). Figure 1C and Table 3 show the effect of colchicine and camptothecin in pre-and post-N6803 cells. Colchicine showed similar levels of cytotoxicity in pre-and post-N6803, but etoposide showed stronger cytotoxicity in pre-than in post-N6803. These results of using colchicine and etoposide, together with our preliminary results (data not shown) of using vincristine, paclitaxel, methotrexate, bleomycin and camptothecin, showed a similar tendency as for pre-and post-N0005. That is, DNA-non-modifying agents showed similar levels of cytotoxicity in pre-and post-N6803, but DNA-modifying agents showed stronger cytotoxicity in prethan post-N6803. Table 4 summarizes the cytotoxic effects of the 11 anticancer agents in TIG-3 and HeLa cells. The mode of effect of anticancer agents in these cell lines is different from that in pre-and post-N0005 cells. Methotrexate and fluorouracil showed weak effects in TIG-3 and HeLa cells. The effect of DNA-modifying and non-modifying agents in TIG-3 and HeLa cells showed no apparent constant difference.
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DISCUSSION
In this study, 4 of 11 anticancer agents without DNA-modifying activity showed similar levels of cytotoxicity in both pre-and post-N0005 cells, but all remaining 7 agents with DNA-modifying activity showed less cytotoxicity in postthan pre-N0005 cells. Because pre-and post-N0005 cells have the same cellular background-even though post-N0005 is immortalized with up-regulation of telomerase, abnormal chromosomes, down regulation of p16/Rb, mutation of p53 gene, and has the ability to grow in soft agarose medium-the increased resistance to DNA-modifying agents is probably linked with factors related to immortalization. In N0005 cells, the expression level of WRN helicase, the product of the causative gene of Werner syndrome, is up-regulated after immortalization. 16, 22) WS patient LCLs and mouse embryonic stem cells lacking normal WRN helicase are more sensitive to camptothecin than corresponding cells with normal WRN helicase, 15, 23) which at least partly explains why post-N0005 cells are more resistant to camptothecin than pre-N0005 cells. Similarly, up-regulation of gene products in DNA repair could be responsible for the increased resistance of post-N0005 cells to DNA-modifying agents. Post-N6803 cells showed resistance to DNA-modifying agents, but post-N6803-2, derived from the original cell line (pre-N6803) as post-N6803, showed less resistance to DNAmodifying agents: post-N6803-2 showed high sensitivity to camptothecin (IC 50 0.0074 mM), etoposide (IC 50 0.12 mM), fluorouracil (IC 50 1.10 mM) and bleomycin (IC 50 0.40 mM) (unpublished preliminary data). Thus, immortalization does not necessarily cause resistance to DNA-modifying agents. Because both post-N0005 and post-N6803, but not post-N6803-2, can form colonies on soft agarose medium, 16 ) the colonyforming ability might be related to the resistance to DNAmodifying agents. The IC 50 ratio for pre-N0005 and Molt-4 varied from 0.3 to 2.0 depending on the DNA-modifying agent. These results together imply that linkage between immortalization and increased resistance to DNA-modifying agents is not necessarily general.
The results of this study suggest that pre-and post-N0005 cell lines can be used to assess and screen anticancer agents. Agents against pre-N0005 and post-N0005 that have an IC 50 ratio less than 1 are possibly DNA-modifying agents, and agents against these cell lines that have an IC 50 ratio near 1 are possibly DNA-non-modifying agents. In this study, pre-N0005 and post-N0005 had an IC 50 ratio of either 1 or less, not markedly exceeding 1, with all the 11 anticancer agents, meaning that the cytotoxicity of these agents in pre-N0005 was equal to or stronger than post-N0005, and anticancer agents are few, if any, that show markedly stronger cytotoxicity in post-N0005 than in pre-N0005. These results, together with the fact that pre-N0005 cells are similar to lymphoblastoid cells generated by antigen stimulation, suggest that most anticancer agents available now have the defect that they have strong adverse effects on actively proliferating normal cells. An agent that induces a markedly higher IC 50 ratio value in pre-N0005 than in post-N0005, meaning that the agent has a markedly stronger cytotoxicity in post-than in pre-N0005 cells, could be an ideal anticancer drug to overcome such a defect, because such an agent is expected to have weaker side effects in actively proliferating hematopoietic cells, lymphoblasts, hair-root cells and gut epithelial cells.
Recently, we observed that the expression of many genes is up-and down-regulated accompanied by immortalization, including the gene of human telomerase reverse transcriptase, as shown by using a micro-array of DNA chip (unpublished observation). The correlation of this phenomenon with the resistance of post-LCLs against anticancer agents is an interesting problem to be elucidated.
Lastly, we like also note that pre-LCL cells and normal Blymphoblasts are apparently different to each other in the following points although they share many properties as discussed thus far. Pre-LCLs have usually a very long lifespan which is probably much longer than the lifespan of normal B-lymphoblasts. 11, 14) Lymhoproliferative disease caused by increase of EBV-transformed lymphoblastoid cells, probably mostly corresponding to pre-LCL cells, by reactivation of EBV after bone-marrow transplantation is known to respond poorly to standard therapy although they could be cured by the infusion with EBV-specific donor-type T-cell lines. 24) Thus, these facts should be taken into consideration when pre-LCL cells are used as a control in assessment and screening of anticancer agents.
To conclude, post-N0005 cells could be used as models of lymphoma cells and pre-N0005 as control cells to assess and screen anticancer agents.
